Serrano, Josefina
Mayo Clinic
Hospital Universitario Reina Sofía
Citations 2
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Stahl, Maximilian , DeVeaux, Michelle, Montesinos, Pau , Itzykson, Raphaël , Ritchie, Ellen K. , Sekeres, Mikkael A. , Brunner, Andrew M. , Komrokji, Rami S. , Bhatt, Vijaya Raj , Al‐Kali, Aref , Cluzeau, Thomas , Santini, Valeria , Fenaux, Pierre , Litzow, Mark R. , Fathi, Amir T. , Kim, Tae Kon , Vey, Norbert , Germing, Ulrich , Bergua, Juan , Gore, Steven D. , Zeidan, Amer M. , Al-Kali, Aref , Litzow, Mark R. , Prebet, Thomas , Komrokji, Rami S , Bergua, Juan Miguel , Sekeres, Mikkael A , Montesinos, Pau , Bhatt, Vijaya Raj , Itzykson, Raphael , Santini, Valeria , Kim, Tae Kon , Barnard, John , Podoltsev, Nikolai , Roboz, Gail J. , Perreault, Sarah , Prébet, Thomas , Verma, Vivek , Serrano, Josefina , Zeidan, Amer M
Leukemia & Lymphoma | July 2, 2018 | Volume: 60 | Issue: 1 | Pages: 246-249
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Stahl, Maximilian , DeVeaux, Michelle, Montesinos, Pau , Itzykson, Raphaël , Ritchie, Ellen K. , Sekeres, Mikkael A. , Brunner, Andrew M. , Komrokji, Rami S. , Bhatt, Vijaya Raj , Al‐Kali, Aref , Cluzeau, Thomas , Santini, Valeria , Fathi, Amir T. , Fenaux, Pierre , Litzow, Mark R. , Kim, Tae Kon , Vey, Norbert , Germing, Ulrich, Bergua, Juan , Gore, Steven D. , Zeidan, Amer M. , Komrokji, Rami S , Bergua, Juan Miguel , Sekeres, Mikkael A , Montesinos, Pau , Bhatt, Vijaya Raj , Itzykson, Raphael , Santini, Valeria , Kim, Tae Kon , Barnard, John , Podoltsev, Nikolai , Roboz, Gail J. , Perreault, Sarah , Prébet, Thomas , Verma, Vivek , Germing, Ulrich , Serrano, Josefina , Zeidan, Amer M
Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 923-932
10.1182/bloodadvances.2018016121
Key Points In the largest study of HMAs in RR-AML to date, 16% of patients achieved CR/CRi and experienced a median OS of 21 months. Low proliferative disease (peripheral blood blasts <5%) was associated with improved response and OS.